title: Increased expression of EphA1 protein in prostate cancers correlates with high Gleason score.
abstract: The erythropoietin-producing hepatocellular (Eph) family of receptor tyrosine kinases regulates a multitude of physiological and pathological processes. EphA1 is the first member of Eph superfamily and is involved in carcinogenesis. The aim of this study was to investigate the expression of EphA1 in prostate cancers cell lines and the tissues, then explore the correlation with the clinicopathologic parameters. The EphA1 transcript expression in prostate cancer cell lines was detected by Quantitative real-time PCR. The expression of EphA1 protein in 138 prostate cancer tissue samples and 21 benign prostate hyperplasia samples were checked by using immunohistochemical staining. EphA1 mRNA was high expressed in LNCap, moderately expressed in 22RV1 and Du145, and lost in PC3. Loss of expression of EphA1 transcript was related to hypermethylation of CpG island around the translation start site. EphA1 protein was differentially expressed in prostate cancers and hyperplasia. Increased expression of EphA1 protein was more frequently detected in prostate cancers than in hyperplasia (P = 0.02), and more often detected in prostate cancer with high Gleason score (P < 0.001). Our data indicate that EphA1 receptor may have roles in carcinogenesis and progression of prostate cancer, and can be a potentially useful target for prognostic and therapeutic application.
authors.affiliation: Southern Medical University Guangzhou, China ; Clinical Medical School of Southern Medical University Nanjing, China ; Department of Pathology, Jinling Hospital, Nanjing University School of Medicine Nanjing, China.
authors.forename: Libo
authors.initials: L
authors.lastname: Peng
authors.forename: Haiyan
authors.initials: H
authors.lastname: Wang
authors.forename: Yingchun
authors.initials: Y
authors.lastname: Dong
authors.forename: Jie
authors.initials: J
authors.lastname: Ma
authors.forename: Juanjuan
authors.initials: J
authors.lastname: Wen
authors.forename: Jinrong
authors.initials: J
authors.lastname: Wu
authors.forename: Xueqing
authors.initials: X
authors.lastname: Wang
authors.forename: Xiaojun
authors.initials: X
authors.lastname: Zhou
authors.forename: Jiandong
authors.initials: J
authors.lastname: Wang
mesh_terms: D000368:Aged; D000369:Aged, 80 and over; D045744:Cell Line, Tumor; D018387:Codon, Initiator; D018899:CpG Islands; D019175:DNA Methylation; D018450:Disease Progression; D015972:Gene Expression Regulation, Neoplastic; D006801:Humans; D008297:Male; D008875:Middle Aged; D060787:Neoplasm Grading; D009367:Neoplasm Staging; D011379:Prognosis; D011470:Prostatic Hyperplasia / Q000235:genetics / Q000401:mortality / Q000473:pathology; D011471:Prostatic Neoplasms / Q000235:genetics / Q000378:metabolism* / Q000473:pathology; D012333:RNA, Messenger / Q000378:metabolism; D036082:Receptor, EphA1 / Q000235:genetics / Q000378:metabolism*; D015854:Up-Regulation
chemical_list: D018387:Codon, Initiator; D012333:RNA, Messenger; D036082:Receptor, EphA1
keywords: EphA1; Prostate cancer; Quantitative real-time PCR; immunohistochemistry
references.citation: Biochem Biophys Res Commun. 2006 Apr 21;342(4):1263-72
references.pmid: 16516143
references.citation: Hum Pathol. 2007 Nov;38(11):1649-56
references.pmid: 17669470
references.citation: Br J Cancer. 2009 Apr 7;100(7):1095-102
references.pmid: 19277044
references.citation: Cancer Res. 2005 Jun 1;65(11):4623-32
references.pmid: 15930280
references.citation: Nat Rev Cancer. 2010 Mar;10(3):165-80
references.pmid: 20179713
references.citation: Int J Cancer. 2009 Jan 1;124(1):88-94
references.pmid: 18821581
references.citation: BMC Cancer. 2005 Sep 20;5:119
references.pmid: 16171530
references.citation: Nat Genet. 2004 Sep;36(9):979-83
references.pmid: 15300251
references.citation: In Vivo. 2009 May-Jun;23(3):387-91
references.pmid: 19454503
references.citation: Int J Cancer. 2010 May 1;126(9):2003-11
references.pmid: 20039322
references.citation: Proc Natl Acad Sci U S A. 2005 Jul 12;102(28):9802-7
references.pmid: 15994236
references.citation: Mod Pathol. 2006 Oct;19(10):1369-77
references.pmid: 16862074
references.citation: CA Cancer J Clin. 2010 Mar-Apr;60(2):70-98
references.pmid: 20200110
references.citation: Mod Pathol. 2009 Jan;22(1):151-60
references.pmid: 19011600
references.citation: Prostate. 1999 Dec 1;41(4):275-80
references.pmid: 10544301
references.citation: Am J Pathol. 2009 Apr;174(4):1492-503
references.pmid: 19264906
references.citation: Gene Expr Patterns. 2006 Oct;6(7):719-23
references.pmid: 16466970
references.citation: Breast Cancer Res. 2008;10(6):217
references.pmid: 19144211
references.citation: J Med Genet. 2006 Jun;43(6):507-11
references.pmid: 16155194
references.citation: Oncol Rep. 2010 Feb;23(2):563-70
references.pmid: 20043122
references.citation: Oncol Rep. 2010 Dec;24(6):1577-84
references.pmid: 21042754
references.citation: Nat Cell Biol. 2010 Dec;12(12):1194-204
references.pmid: 21076414
references.citation: Oncogene. 2005 Aug 25;24(36):5637-47
references.pmid: 16007213
references.citation: Science. 1987 Dec 18;238(4834):1717-20
references.pmid: 2825356
references.citation: J Cell Sci. 2009 Jan 15;122(Pt 2):243-55
references.pmid: 19118217